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Abstract
The extracellular matrix (ECM) is a determining factor in the tumor microenvironment that 
restrains or promotes malignant growth. In this report, we show how the molecular chaperone 
protein Hsp47 functions as a nodal hub in regulating an ECM gene transcription network. A 
transcription network analysis showed that Hsp47 expression was activated during breast cancer 
development and progression. Hsp47 silencing reprogrammed human breast cancer cells to form 
growth-arrested and/or non-invasive structures in 3D cultures, and to limit tumor growth in 
xenograft assays by reducing deposition of collagen and fibronectin. Co-expression network 
analysis also showed that levels of microRNA-29b and 29c were inversely correlated with 
expression of Hsp47 and ECM network genes in human breast cancer tissues. We found that 
miR-29 repressed expression of Hsp47 along with multiple ECM network genes. Ectopic 
expression of miR-29b suppressed malignant phenotypes of breast cancer cells in 3D culture. 
Clinically, increased expression of Hsp47 and reduced levels of miR-29b and 29c were associated 
with poor survival outcomes in breast cancer patients. Our results show that Hsp47 is regulated by 
miR-29 during breast cancer development and progression, and that increased Hsp47 expression 
promotes cancer progression in part by enhancing deposition of ECM proteins.
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Introduction
Extracellular matrix (ECM) molecules, including collagen proteins, fibronectin, 
proteoglycans, and glycoproteins provide essential physical scaffolds to maintain tissue 
structure and various biochemical signals to modulate cellular function (1, 2). Around 300 
ECM proteins have been identified from the human genome using bioinformatics tools and 
proteomics techniques (3). Expression and deposition of collagen and fibronectin are 
significantly greater in breast cancer tissue than in non-malignant mammary tissue (4). 
Enhanced deposition and cross-linking of collagen and other ECM proteins increase tissue 
stiffness, disrupt normal tissue architecture and enhance both tumor growth and invasion (5, 
6). Moreover, collagen and fibronectin have been identified as prognostic markers and are 
associated with cancer recurrence (7, 8). Taken together, these results indicate that increased 
expression and deposition of these ECM proteins are crucial for cancer development and 
progression. But how these ECM proteins are coordinately regulated during breast cancer 
progression remains unknown.
Gene co-expression network analysis is a systems biology approach using correlation 
statistics as pairwise similarity measurements between gene expression profiles, followed by 
either direct correlation thresholding or a combination of significance level tests with 
correlation thresholding (9). This approach identifies strong relationships that connect 
transcripts' regulatory patterns to the functional organization of the cell, and this method has 
been successfully used to identify gene networks associated with skin tumor susceptibility 
(10). Using microarray data generated from hundreds of human breast cancer tissues, gene 
co-expression network analysis identified two microenvironment gene networks (11). One 
of the networks represents the coordinated action of ECM remodeling in breast cancer 
tissue, and is associated with activation of the TGF-β pathway (11). The TGF-β pathway 
regulates a broad range of responses including microenvironment remodeling (12). In the 
canonical TGF-β signaling pathway, binding of TGF-β to its receptor activates the 
transcription factor Smad and modulates gene transcription (13). A major effect of TGF-β on 
the microenvironment is the deposition of ECM via induction of collagen types I, III, IV, 
VII and X, fibronectin, and proteoglycans (14).
Expression and deposition of ECM components are subject to tight spatiotemporal 
regulation during normal development and cancer progression (15), and the importance of 
cancer cells in ECM deposition and remodeling has recently been demonstrated (16, 17). Dr. 
Hynes's laboratory showed that human cancer cells generate a variety of human ECM 
proteins in a xenograft model system (18). Inhibition of collagen production in breast cancer 
cells by blocking P4HAs significantly reduced tumor growth and metastasis in the mouse 
xenograft model (19, 20). These studies indicate that cancer cells are an active and important 
component in ECM reorganization. Therefore, an understanding of how ECM proteins are 
coordinately regulated in cancer tissues, and identifying the key factors that integrate the 
ECM network are vital in order to target and inhibit ECM-dependent cancer progression.
The SerpinH1 gene encodes a heat-inducible protein (Hsp47) and locates at chromosome 
11q13.5, one of the most frequently amplified regions in human cancer (21). Enhanced 
expression of Hsp47 has been detected in cancer tissue (22, 23). Hsp47 has been identified 
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as a molecular chaperon that is required for the proper folding and secretion of collagen 
proteins. Hsp47 transiently interacts with the triple helix region of newly synthesized 
procollagen in the endoplasmic reticulum, and this interaction is required for the proper 
folding and secretion of collagen proteins (24-26). Inhibition of Hsp47 binding is thought to 
be an efficient strategy for blocking collagen deposition and ECM remodeling (27). Deletion 
of Hsp47 in mice severely impairs maturation of collagen fibers and basement membrane 
formation, and also causes embryonic lethality (28). These data indicate that Hsp47-
regulated collagen maturation is crucial for normal embryonic development. However, the 
function and regulation of Hsp47 during breast cancer development and progression remains 
unknown.
Here, we show that expression of Hsp47, a hub of the ECM transcription network, is 
associated with cancer progression and poor clinical outcome in human breast cancer 
patients. Silencing Hsp47 expression reprogrammed breast cancer cells to form polarized 
and/or non-invasive structures in 3D culture and significantly inhibited tumor growth in 
vivo, accompanied by reduced deposition of collagen and fibronectin. Expression of Hsp47 
and the ECM network genes is inversely correlated with miR-29b and 29c in human breast 
cancer tissues. We further demonstrate that Hsp47 and multiple genes in the ECM 
transcription network are repressed by miR-29b and 29c in mammary epithelial cells. These 
results indicate that Hsp47, as a downstream target of miR29, promotes breast cancer 
progression by modulating ECM deposition.
Materials and Methods
Antibodies and reagents
5-ethynyl-2′-deoxyuridine (Edu) staining kit was obtained from Invitrogen. Matrigel® and 
type I collagen were purchased from BD Bioscience. ShRNA constructs selectively 
targeting HSP47, collagen IV or fibronectin were purchased from Sigma (MISSION shRNA 
library). Antibodies to the following proteins were obtained as indicated: Hsp47 and lamin 
A/C (Santa Cruz); tubulin and α6 integrin (Millipore); Flag (Sigma); collagen I, collagen IV 
and fibronectin (Abcam).
Cell culture
HMT-3522, S1, and T4-2 cells (a kind gift from Dr. Mina J Bissell) were maintained as 
previously described (29). MDA-MB-231 and BT549 (ATCC) cells were cultured in 
DMEM/F12 (Sigma), Hs578T in DMEM (Sigma), both supplemented with 10% fetal bovine 
serum, 10 units/ml of penicillin and 0.1 mg/ml of streptomycin (Invitrogen). In 3D culture, 
cells were plated on Matrigel® and maintained in the culture medium containing 5% 
Matrigel. T4 cells were seeded at a density of 2.1×104 cells per cm2; while MDA-MB-231 
and Hs578T (ATCC) were seeded at 1.4×104 cells per cm2. For production of lentivirus, 
293FT cells were transfected with shRNA vector plus packaging vectors using FuGENE 
(Promega). Culture supernatants containing viral particles were collected 48h after 
transfection. Cells were infected with lentivirus and selected using puromycin for at least 
three days. Cell migration and invasion assay were performed as previously described (30).
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Quantitative RT-PCR
Quantitative RT-PCR was carried out as previously described (30). The relative 
quantification of gene expression for each sample was analyzed by the ΔCt method. The 
following primers were used to amplify HSP47: 5′-TGAAGATCTGGATGGGGAAG-3′ 
AND 5′-CCGCACTAGGAAGATGAAGG-3′; COL1A1: 5′-
ATGGATTCCAGTTCGAGTATGGC-3′ AND 5′-CATCGACAGTGACGCTGTAGG-3′; 
COL3A1: 5′-AGGTCCTGCGGGTAACACT-3′ AND 5′ 
ACTTTTCACCCTTGACACCCTG-3′; 18S rRNA: 5′-ACCTGGTTGATCCTGCCAGT-3′ 
AND 5′-CTGACCGGGTTGGTTTTGAT-3′. For quantification of miRNA expression, 
TaqMan probes were used according to the manufacture's protocol (Applied Biosystems). Ct 
values were normalized to RNU44.
Transfection and lentivirus infection
The miRNA mimics and inhibitors were designed and synthesized by GenePharma. Cells 
were plated in 6-well plate to 70% confluence. For each well, 20 μM miRNA were added 
into 250 μl Opti-MEM, with 5 μl of Lipofectamine 2000 (Invitrogen). The mixture was 
added to cells and incubated for 6 h before replacing with normal culture medium. Total 
RNA was prepared 48 h after transfection and used for RT–PCR.
Western blot analysis and immunofluorescence
Western blots were performed as previously described (30). Exposures were acquired and 
quantified using a FluroChem HD2 (Alpha Innotech).
Cells in Matrigel® were smeared on slides, dried briefly, then fixed with 4% 
paraformaldehyde (PFA)/PBS and permeabilized in 0.5 % Triton X-100/PBS. Samples were 
blocked with 1% BSA and 5% goat serum/PBS for 1h, followed by incubation with the 
primary antibody in blocking buffer for 2h at room temperature and the secondary antibody 
for 50min at room temperature. Images were acquired with an Olympus FV1000 microscope 
using a 1.3 NA 40× objective with oil immersion.
Xenograft experiment
Six-week-old female SCID mice were randomly grouped and subcutaneously injected with 
5×106 shCtrl (control) or shHSP47 T4-2 cells. Tumors were measured with a caliper every 
three days for three weeks to analyze tumor growth. Tumor volume was also monitored 
using an in vivo imaging system (IVIS®). The experiment was terminated with the sacrifice 
of all mice, and tumor fragments obtained at necropsy were weighed, imaged, and fixed with 
4% PFA for histology. For the orthotopic mammary tumor experiments, female SCID mice 
(six weeks old) were injected with 1×106 sh-control or shHsp47 MDA-MB-231/Luc cells 
into mammary fat pad. Tumor volume was measured using IVIS. All procedures were 
performed within the guidelines of the Division of Laboratory Animal Resources at the 
University of Kentucky.
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Masson's trichrome staining and immunohistochemistry analysis
Xenograft tumor sections were de-paraffinized and rehydrated. Samples were re-fixed with 
Bouin's solution at 60°C for 60 minutes, stained in Weigert's working hematoxyin for 10 
minutes, and then stained in Biebrich scarlet-acid fuchsin solution for 5 minutes. Sections 
were incubated in phosphomolybdic-phosphotungstic acid solution for 10 minutes, and then 
were transferred to aniline blue solution and incubated for 5 minutes. Images were taken 
with a Nikon microscope. The percentage of collagen was quantified by calculating the ratio 
of the blue staining (collagen) area to the total area of the tumor section using Imagescope 
analysis software (19). Immunohistochemistry analysis was performed as described 
previously (20).
Co-expression network analysis
The gene co-expression network analyses were performed with Cytoscape as previous 
described (11). The expression data of microRNAs and the ECM network genes were 
obtained from microRNA and gene microarray profiles generated from 97 human breast 
cancer tissues (GSE19536).
Kaplan-Meier survival analysis and other statistical analysis
We examined Hsp47 expression in 404 breast tumor expression arrays taken from studies by 
van de Vijver et al. (31) (n=295) and Chin et al. (32) (n=118). In each dataset, the tumor 
samples were evenly divided into Hsp47 low, Hsp47 high, and Hsp47 medium based on the 
Hsp47 mRNA level. This method allowed us to compare relative Hsp47 expression levels 
across both data sets fused as a single group of patients. Significant differences in survival 
time were assessed using the Cox proportional hazard (log-rank) test.
Analysis of Hsp47mRNA levels in normal and malignant tissues was performed in the 
TCGA breast cancer dataset downloaded from Oncomine. The association between mRNA 
levels of Hsp47 with other genes and microRNAs was evaluated with Spearman correlation 
analysis. All experiments were repeated at least twice. Results are reported as mean ± the 
standard error of the mean; the significance of difference was assessed by independent 
Student's t-test. P<0.05 represents statistical significance and P<0.01 represents sufficiently 
statistical significance. All reported P-values were two-tailed. Statistical analysis was 
conducted with SigmaPlot (Systat Software, Inc.) and SAS (version 9.2; SAS Institute Inc.).
Results
Hsp47 is associated with expression of the ECM network genes during breast cancer 
development and progression
Remodeling of the ECM microenvironment is a necessary event for breast cancer 
development and progression. Using gene co-expression network analysis, we discovered a 
co-expression network that integrates the coordinated action of ECM remodeling from 
hundreds of human breast cancer tissues (11), and identified Hsp47 (SerpinH1) as a node of 
this network (Figure 1A). Hsp47 mRNA levels significantly correlated with the expression 
of collagen I (Col1A1), IV (Col4A1), and fibronectin (FN1) in human breast cancer tissues 
(Figure 1B, C, D) as well as in 24 human breast cancer cell lines (Supplemental Table 1). 
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These correlations suggest a functional connection and/or co-regulation between Hsp47 and 
these ECM proteins. Using the TCGA breast cancer dataset, we determined that the 
expression of the ECM network genes and Hsp47 was significantly increased in cancer 
samples compared with normal mammary tissue (Figure 1E, F). The increased mRNA levels 
of Hsp47 were also detected in other types of cancers (Supplemental Figure 1A). The 
protein levels of Hsp47 in breast cancer cell lines were higher than the levels in non-
malignant cell lines (Figure 1G). Among breast cancer cell lines, Hsp47 levels were higher 
in basal-like breast cancer when compared with the luminal cancer cells (Figure 1H) by 
quantitative RT-PCR analysis. These results indicate that expression of Hsp47 and the ECM 
transcription network is activated during breast cancer development. However, roles of 
Hsp47 in regulating breast cancer development and progression remain to be addressed.
Hsp47 regulates the malignant phenotypes of breast cancer cells in 3D culture
To determine function of enhanced Hsp47 expression in breast tumor progression, we 
silenced Hsp47 in four breast cancer cell lines, T4-2, MDA-MB 231, BT549 and Hs-578T, 
with two shRNAs (Figure 2A). The 3D tissue culture model provides a physiologically-
relevant microenvironment for monitoring tissue morphogenesis of non-malignant and 
malignant cells (29, 33). In this model, malignant T4-2 cells form disorganized and 
proliferative structures (29). Knockdown of Hsp47 reprogrammed the malignant T4-2 cells 
to form polarized structures with reduced colony size in 3D culture (Figure 2B, C). MDA-
MB 231, BT549 and Hs-578T cells form stellate structures in 3D culture, reflecting 
decreased cell-cell interactions and enhanced cell invasiveness (Figure 2D) (34). Silencing 
Hsp47 in MDA-MB 231, BT549, and Hs-578T cells significantly reduced branching in 3D 
culture (Figure 2D, E). Knockdown of Hsp47 also significantly reduced proliferation of 
T4-2 and MDA-MB 231 cells in 3D culture and inhibited cell invasion in the Transwell 
assay (Figure 2F, G). Non-malignant S1 cells contain low levels of Hsp47 compared with 
their malignant T4-2 counterpart (Figure 1E), and form polarized acini in 3D culture. 
Ectopic expression of Hsp47 disrupted the polarized acinus structures and increased colony 
size (Figure 2H), but Hsp47 expression failed to induce colony formation in non-malignant 
cells (Supplemental Figure 1B). The results from these gain and loss of function 
experiments indicate that Hsp47 promotes cancer progression in 3D culture by enhancing 
cell proliferation and invasion.
Since Hsp47 levels are associated with expression of collagen and fibronectin, we 
investigated whether Hsp47 modulates 3D malignant phenotypes of breast cancer cells via 
enhanced secretion and deposition of ECM proteins. Silencing Hsp47 expression in breast 
cancer cells reduced the levels of collagen I, IV, and fibronectin in the conditioned medium, 
but had little effect on the cellular protein levels (Figure 3A). It has been reported that 
Hsp47-deficiency induces procollagen aggregates in the endoplasmic reticulum, and the 
arrogated protein is subsequently degraded by the autophagy-lysosome pathway (35). This 
degradation may explain why we did not detect accumulation of ECM protein in Hsp47-
silenced cells. Deposition of collagen IV and fibronectin was also down-regulated in Hsp47-
silenced T4-2 cells in 3D culture (Figure 3B). In addition, multiple components of the ECM 
transcription network, such as collagen III and V have been identified as targets of Hsp47 
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(25). Thus, Hsp47 may serve as a functional hub to facilitate maturation of multiple proteins 
in the ECM network.
Increased fibronectin production is associated with and promotes breast cancer progression 
(17), but the functional roles of collagen IV in breast cancer have not been investigated. We 
showed that secretion of collagen IV and fibronectin was enhanced in malignant T4-2 cells 
compared to non-malignant S1 cells (Figure 3C). By analyzing the published microarray 
datasets in the Oncomine, we found that mRNA levels of Col4A1 and FN1 were 
significantly upregulated in many solid tumors (Supplemental Figure 1A). To determine 
whether enhanced production of collagen IV and fibronectin is crucial for the malignant 3D 
phenotypes of T4-2, we silenced Col4A1 or FN1 expression with shRNA. Knockdown of 
Col4A1 or FN1 significantly reduced colony size of T4-2 cells in 3D culture and increased 
number of polarized colonies (Figure 3D, E, F, G, H, I). However, reduction of collagen I 
expression in T4-2 cells had little effect on the malignant phenotypes in 3D culture (data not 
shown). Knockdown of fibronectin in MDA-MB 231 cells significantly reduced invasive 
branching in 3D culture (Figure 3J), but silencing collagen IV in MDA-MB 231 cells is not 
sufficient to suppress invasive branching in 3D culture (data not shown). To determine 
whether exogenous fibronectin can restore invasive behavior in Hsp47-silenced tumor cells, 
we performed a number of rescue experiments. We found that exogenous fibronectin 
restored cell migration and partially rescued invasive behavior in Hsp47-silenced MDA-MB 
231 cells (Figure 3K, L, M). These results suggest that Hsp47 promotes breast cancer 
progression in part by enhancing secretion and deposition fibronectin and collagens.
MiR-29b and 29c repress expression of Hsp47 and the ECM network genes
MicroRNA regulates gene expression by targeting the three prime untranslated regions 
(3′UTR) of mRNA. Given the small sequence match required, an individual microRNA can 
regulate hundreds of genes (36, 37). Thus, we hypothesized that microRNA was involved in 
the activation of Hsp47 and the ECM network during breast cancer progression. We found 
that the seed complementary sites for miR-29, let-7, miR-200, miR-181 and miR-300 were 
enriched in the 3′UTR region of the ECM network genes. Using co-expression network 
analysis, we identified a number of microRNAs, including miR-29b and 29c that were 
negatively correlated with expression of the ECM network genes in human breast cancer 
tissues (Figure 4A). MiR-29b has recently been identified as a metastasis suppressor and 
functions by altering tumor microenvironment (38). A potential binding site for miR-29 was 
also identified in the 3′UTR region of the Hsp47 gene (Figure 4B), and this binding site is 
conserved among species (Figure 4B). Moreover, the 3′UTR regions from about half of 
ECM network genes (19/41) contain miR-29 binding sites (Supplemental Figure 2A).
To examine function of miR-29b and 29c in regulating Hsp47 and the ECM network genes, 
we introduced microRNA mimics and inhibitors into malignant and non-malignant 
mammary epithelial cell lines. Transfection of miR-29 mimics reduced the protein levels of 
Hsp47 in breast cancer cells (Figure 4C), while introduction of miR-29b and 29c inhibitors 
enhanced the expression of Hsp47 in the non-malignant mammary epithelial cell line 
MCF10A (Figure 4D). Quantitative RT-PCR demonstrated that miR-29b and 29c mimics 
also inhibited the expression of the ECM network genes that contain miR-29 binding sites in 
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the 3′UTR region (Figure 4E), suggesting that the ECM microenvironment is regulated by 
miR-29 at the transcriptional network level. To determine whether miR-29 regulates Hsp47 
expression by directly targeting the 3′ UTR, we ligated the Hsp47 3′ UTR region with 
putative miR-29 binding sites downstream of the coding sequence of luciferase. Ectopic 
expression of miR-29b significantly reduced the reporter activity (Figure 4F). Mutation in 
the seed complementary site reduced miR-29b-mediated repression for Hsp47 (Figure 4F). 
Thus, miR-29 inhibits Hsp47 expression by directly targeting to the 3′ UTR region.
To determine function of miR-29b in suppressing breast cancer progression, the miR-29b 
expression vector was stably transfected in breast cancer cells. Ectopic expression of 
miR-29b in T4-2 cells significantly reduced colony size in 3D culture (Figure 4G, H). 
Introduction of miR-29b in MDA-MB 231 cells suppressed invasive branching (Figure 4I, 
J), which replicates the phenotype of Hsp47-silenced cells in 3D culture. To examine the 
clinical association between miR-29 and Hsp47 expression during breast cancer progression, 
we performed Spearman correlation analysis using the microRNA and mRNA expression 
profiles generated from 97 human breast cancer tissues (39). We found that miR-29b (Figure 
4K) and 29c (Figure 4L) negatively correlated with mRNA levels of Hsp47 in human breast 
cancer tissues. These results suggest that downregulation of miR-29b and 29c induces 
Hsp47 expression during breast cancer progression.
MiR-29 mediates TGF-β-induced Hsp47 expression
Co-expression network analysis revealed that expression of the ECM network was 
associated with activation of the TGF-β pathway (11). Treatment with TGF-β induced 
Hsp47 transcription in non-malignant S1 and MCF-10A cells (Figure 5B), while blocking 
the TGF-β pathway with SB431542 (a TGFBR inhibitor) reduced Hsp47 expression in 
MDA-MB 231 cells (Figure 5C). We also found that mRNA levels of Hsp47 and TGF-β 
were significantly correlated in human breast cancer tissues (Figure 5A) and cell lines 
(Supplemental Figure 2B). These results indicate that Hsp47 is regulated by the TGF-β 
pathway in breast cancer cells.
Next, we examined whether miR-29 is a downstream target of the TGF-β signaling during 
breast cancer progression. TGF-β treatment significantly suppressed miR-29b expression in 
non-malignant MCF-10A cells (Figure 5D), while incubation with SB431542 enhanced 
miR-29b expression in MDA-MB 231 cells (Figure 5E, F). Importantly, transfection of 
miR-29b or 29c inhibitors rescued Hsp47 expression in SB431542-treated breast cancer 
cells (Figure 5G). We also found that expression of miR-29b and the TGF-β ligand were 
negatively correlated in human breast cancer tissues (Figure 5H). Therefore, miR-29b at 
least partially mediates the TGF-β-induced Hsp47 expression and ECM remodeling during 
breast cancer development and progression.
Enhanced Hsp47 expression promotes tumor growth in vivo and correlates with poor 
prognosis
To determine the in vivo function of Hsp47 during breast cancer progression, control and 
Hsp47-silenced T4-2 cells were subcutaneously injected into the flanks of female mice. 
Tumor growth was significantly reduced in the Hsp47-silenced group compared to the 
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control group (Figure 6A, B). Cancer cells in the Hsp47-silenced tumors were less 
proliferative compared to the cells in the control group (Figure 6C), which is consistent with 
reduced tumor growth in Hsp47-silenced tumors. Masson's trichrome staining demonstrated 
significantly less collagen deposition in the Hsp47-silenced tumors when compared to the 
control T4-2 tumors (Figure 6D). The function of Hsp47 in regulating tumor growth was 
also verified in an orthotopic mammary tumor model. Control and Hsp47-silenced MDA-
MB 231 cells were transplanted into the mammary fat pads of female SCID mice. We found 
that silencing Hsp47 expression also inhibited tumor growth in the mammary fat pads 
(Figure 6E). Reduced collagen and fibronectin deposition was also observed in 
orthotopically placed Hsp47-silenced tumors (Supplemental Figure 3A).
To address the clinical relevance of enhanced Hsp47 expression in human breast cancer, we 
assessed the association between mRNA levels of Hsp47 and patient survival using the 
published microarray data generated from more than 400 breast cancer tissue samples (31, 
32). Breast cancer patients were evenly divided into three groups based on the Hsp47 
mRNA levels (low, moderate and high). Kaplan-Meier log rank analysis showed that 
patients whose tumor had higher Hsp47 expression levels had a significantly shorter overall 
and recurrent-free survival periods (Figure 7A, B). Similar results were also obtained in a 
large cohort microarray dataset containing 4142 breast cancer samples (Supplemental Figure 
3B). Moreover, high grade tumors expressed more Hsp47 compared to low grade tumors 
(Figure 7C). These results indicate that activation of Hsp47 correlates with breast cancer 
progression. Since miR-29b and 29c are inversely correlated with Hsp47, we further 
analyzed the association between these two microRNAs and clinical outcomes. We found 
that downregulation of miR-29b and 29c was associated with poor prognosis in human 
breast cancer patients (Figure 7D, E). These results suggested that activation of miR-29/
Hsp47 axis is associated with a poor clinical outcome.
Discussion
Discovery of the ECM transcription network suggests that expression of the ECM proteins is 
coordinately regulated during breast cancer development and progression (11). In the 
present study, we demonstrate that Hsp47 is a hub of the ECM network and modulates 
tumor microenvironment by regulating deposition of multiple ECM proteins. We have 
shown that upregulation of Hsp47 is associated with development of solid tumors, including 
colon, brain, esophageal, and head and neck cancer. Increased Hsp47 mRNA levels 
correlated with a poor clinical outcome in breast cancer patients. Silencing Hsp47 
reprogrammed breast cancer cells to form polarized or non-invasive structures in 3D culture 
and inhibited tumor growth in the xenograft mammary tumor model. These results indicate 
that the increased Hsp47 expression is crucial for tumor progression.
Knockdown of Hsp47 in breast cancer cells reduced secretion and deposition of ECM 
proteins, including fibronectin and collagens. Increased expression and deposition of 
fibronectin in breast cancer tissue are associated with poor prognosis, and it has also been 
detected in metastatic niches (40, 41). Fibronectin promotes cancer progression by 
enhancing cell proliferation, invasion and colonization (17, 41). We found that exogenous 
fibronectin partially restored invasive behavior in Hsp47-silenced breast cancer cells. These 
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results indicate that fibronectin is an important downstream target of Hsp47 in promoting 
breast cancer progression. However, fibronectin could not completely restore malignant 
phenotypes in Hsp47-silenced cells, suggesting that collagen and other Hsp47 targeted 
proteins also contribute to this process. Thus, it is crucial to characterize the Hsp47-targeted 
proteins using unbiased high throughput proteomic analysis in the future. The information 
obtained from the high throughput assay may be essential for a comprehensive 
understanding of how Hsp47 promotes cancer progression.
Hsp47 has been identified as a collagen-binding protein, and is considered a collagen-
specific chaperon (24). Our study confirmed the function of Hsp47 in regulating collagen 
deposition and identified fibronectin as a new target in breast cancer cells. We showed that 
mRNA levels of Hsp47 and fibronectin were significantly correlated in human breast cancer 
tissue and cells lines. Hsp47 silencing reduced secretion and deposition of fibronectin in 
breast cancer cells. Fibronectin does not contain Gly-X-Y repeats that form triple helix 
structure; it would be interesting to determine whether Hsp47 binds to fibronectin in order to 
facilitate its assembly and deposition. It has been shown that assembly and deposition of 
fibronectin depend on fibronectin-integrin interaction and are induced by cell contractility 
and Rho activation (42-44). Fibronectin assembly is impaired in FAK-null cells, indicating 
FAK is a critical regulator of fibronectin deposition (45). Our unpublished data showed that 
knockdown of Hsp47 reduced the number and size of focal adhesion in breast cancer cells. It 
is plausible that Hsp47 regulates fibronectin deposition indirectly by enhancing cell 
contractility and FAK activity.
Cancer cells are an important source of ECM in cancer tissue and deposit a significant 
amount collagen, fibronectin and tenascin-C (4, 16). However, roles of cancer cell-produced 
ECM in the progression of breast cancer have not been appreciated until recently. We found 
that breast cancer cell lines express multiple ECM protein genes and their mRNA levels 
correlated with Hsp47 expression. Collagen IV and fibronectin expression was enhanced 
during breast cancer development. Silencing Col4A1 or FN1 reprogrammed the malignant 
T4-2 cells to form polarized spheroid structures. Interestingly, the exogenous collagen IV in 
Matrigel® cannot rescue the malignant phenotypes of Col4A1-silenced T4-2 cells in the 3D 
culture. These results suggest that cancer cell-deposited collagen IV is crucial for disruption 
of polarized acinus structures. Although cancer cells and stromal cells in breast cancer tissue 
both generate significant amount of ECM proteins, the roles of these proteins in cancer 
progression may be different. The fibrillar collagen produced by cancer-associated fibroblast 
enhances fibrosis and cancer stiffness, and subsequently promotes cancer progression (46, 
47). The ECM molecules deposited by stromal cells also provide physical and biochemical 
cues to direct cancer cell migration and invasion. We found that silencing Hsp47 reduced 
production of collagen and fibronectin in cancer cells and inhibited tumor growth in 
xenograft model. Thordur Oskarsson et al have shown that cancer cell-produced tenascin C 
enhances dissemination and survival of tumor cells during the early phases of metastasis by 
generating a niche that is susceptible to metastasis (16). These results suggest that ECM 
molecules generated by cancer cell are crucial for cell survival and proliferation as essential 
components of the cancer cell niche.
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We showed that miR-29b and 29c were negatively correlated with expression of the ECM 
network genes in human breast cancer tissues. Introduction of miR-29 mimics significantly 
reduced expression of multiple ECM network genes. In addition, it has been shown that 
collagen types I, III, and IV, and ELN expression are regulated by miR-29 during the 
development of murine abdominal aortic aneurysms (48). These results indicate that 
miR-29b and 29c regulate ECM remodeling through repression of the transcription network. 
We identified Hsp47 as a direct target of miR-29b and 29c. A recent study also shows that 
miR-29a represses Hsp47 expression in glioma (49). Given the important function of Hsp47 
in ECM protein maturation, miR-29 can also modulate secretion and deposition of ECM 
proteins by suppressing Hsp47 expression, which provides an alternative pathway for 
miR-29 to regulate ECM microenvironment. It has been shown that miR-29 is inhibited by 
TGF-β in systemic sclerosis and fibrosis (50). Jonathan Chou et al. demonstrate that TGF-β 
is a miR-29 target gene (38). Together these results suggest a feedback loop between the 
TGF-β pathway and miR-29. We showed that expression of TGF-β, miR-29b, and Hsp47 are 
significantly correlated in human breast cancer tissues. Therefore, miR-29b may serve as an 
important mediator of the TGF-β pathway to regulate expression of Hsp47 and the ECM 
network genes. Transcription factor GATA3 maintains luminal mammary epithelial cell 
differentiation, induces miR-29b expression in luminal-type breast cancers and inhibits 
cancer metastasis (38). We found that GATA3 and Hsp47 expression is inversely correlated 
in human breast cancer tissues (Supplemental Figure 4A), and that Hsp47 is highly 
expressed in basal-like breast cell lines (Figure 1H) and ER negative breast cancer tissues 
(Supplemental Figure 4B). These results suggest that Hsp47 is upregulated in basal-like 
cancer and may contribute to cancer metastasis.
In summary, reduced miR-29 levels and increased Hsp47 expression are crucial for 
activation of the ECM network and remodeling of the ECM microenvironment in breast 
cancer tissue. Given the important function of ECM microenvironment at multiple stages of 
cancer progression, these findings provide insights into novel strategies to suppress ECM-
dependent cancer progression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Hsp47 expression is upregulated during breast cancer development and correlated 
with mRNA levels of multiple ECM protein genes
A) An ECM transcription network was identified by co-expression network analysis. Hsp47 
(Serpinh1) is a hub of the ECM network. (B-D) Scatter plot of correlated mRNA levels 
between Hsp47 and (B) Col1A1, (C) Col4A1, and (D) FN1 in normal and malignant breast 
tissues (n=593). Expression data were obtained from the TCGA microarray dataset 
(Oncomine). (E) Box plots showed the mRNA levels of the ECM network genes in breast 
cancer tissues (n=532) and normal tissues (n=61), p<0.001). (F) Box plots showed the 
mRNA levels of Hsp47 in breast cancer tissues (n=532) and normal tissues (n=61), 
p<0.001). Data were obtained from the TCGA microarray dataset. (G) Western blot showed 
expression of Hsp47 in breast cancer cells (BT549, MDA-MB 231, T4-2, and SUM-140) 
and non-malignant cells (S1 and MCF10A). (H) Quantitative RT-PCR analyzing expression 
of Hsp47 gene in basal type of breast cancer (red, n=7) and luminal cancer cells (gray, n=8).
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Figure 2. Silencing Hsp47 suppresses malignant phenotypes of breast cancer cells in 3D culture
(A) T4-2 cells were infected with lentivirus containing control shRNA and Hsp47 shRNA. 
The knockdown efficiency was assessed by Western blot. (B) Phase and confocal images 
showed the morphology and α6-integrin staining (basal marker, green) of control and 
Hsp47-silenced T4-2 cells. (C) Colony size of the control and Hsp47-silenced T4-2 cells in 
3D culture, n=50, ** p<0.01. (D, E) Control and Hsp47-silenced MDA-MB-231, BT549, 
and Hs-578T cells were cultured in 3D for 4 days. (D) Phase images showed the organoid 
morphology in 3D culture. (E) Quantitative data showed that the branching structures was 
significantly reduced in Hsp47-silenced MDA-Mb 231 cells, n=35, ** p<0.01. (F) Cell 
proliferation was examined by the 5-ethynyl-2′-deoxyuridine (EdU) labeling assay. Bar 
graph represents the ratio of EdU positive cells in control and Hsp47-silenced T4-2 and 
MDA-MB 231 cells, n=3; * p<0.05. (G) Cell invasion was assessed by the Transwell assay. 
Results indicate that silencing Hsp47 significantly inhibits cell invasion in T4-2 and MDA-
MB 231 cells, n=4; * p<0.05, ** p<0.01. (H) Phase and confocal images showed the 
morphology and α6-integrin staining (basal marker, green) of the control and Hsp47-
expressing S1 cells. The cells were cultured in 3D Matrigel™ for 4 days.
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Figure 3. Knockdown of Hsp47 inhibits secretion and deposition of collagen and fibronectin
(A) The secreted and cellular levels of collagen I (Col I), IV (Col IV), fibronectin (FN) and 
were analyzed by Western blot in control and Hsp47-silenced T4-2 cells. (B) Confocal 
images showed the deposition of collagen IV and fibronectin in control and Hsp47-silenced 
T4-2 cells. (C) Expression of collagen IV and fibronectin (FN) in S1 and T4-2 cells were 
analyzed by Western blot. (D, E) Phase images (D) and quantification (E) of the colony size 
of control and Col4A1-silenced T4-2 cells in 3D culture, n=100; ** p<0.01. (F) Basal 
polarity in control and Col4A1-silenced T4-2 cells was assessed by α6-integrin staining; the 
percentage of polarized colonies was determined, n=40; ** p<0.01. (G) Bar graph showing 
the percentage of EdU positive cells in control and Col4A1-silenced T4-2 cells, n=3; ** 
p<0.01. (H, I) Phase images (H) and quantification (I) of the colony size of control and 
FN1-silenced T4-2 cells in 3D culture, n=100, ** p<0.01. (J) Phase images and 
quantification of invasive branch structures in control and FN1-silenced MDA-MB 231 
cells. (K, L) Cell migration (K) and invasion (L) of Hsp47-silenced MDA-MB 231 cells 
were analyzed in the presence and absence of exogenous fibronectin (10 μg/ml) (FN), 
*p<0.05; ** p<0.01. (M) Phase images of invasive phenotypes of Hsp47-silenced MDA-MB 
231 cells in 3D culture. Matrigel was mixed with fibronectin (12.5 μg/ml) (FN) or same 
volume of PBS.
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Figure 4. MiR-29b and 29c repress expression of Hsp47 and ECM network genes during breast 
cancer progression
(A) Co-expression network analysis showed that miR-29b and 29c were associated with the 
ECM transcription network. (B) Sequence alignment showed the miR-29 binding site in the 
3′UTR region of Hsp47 gene (SerpinH1) (Upper panel). The target site of miR-29 in Hsp47 
3′-UTR is highly conserved among mammalian species (Lower panel). (C) Hsp47 protein 
levels were assessed by Western blot in control and miR-29 mimic-transfected T4-2 cells. 
(D) Hsp47 protein levels were assessed by Western blot in control and miR-29 inhibitor-
transfected MCF10A cells. (E) Quantitative RT-PCR analysis of the expression of Hsp47 
and the ECM network genes in control and miR-29 mimic-transfected cells; n=4, ** p<0.01; 
* p<0.05. (F) Luciferase reporter analysis showed that miR-29b inhibited Hsp47 expression 
by targeting the seed complementary sequence in the 3′UTR region. pGL3-Hsp47-3′-UTR 
reporter plasmid in which the luciferase-coding sequence had been fused to the 3′-UTR of 
firefly luciferase was cotransfected into HEK293 cells with negative control (white 
columns) or miR-122 duplex (red columns). Hsp47-Mu indicates the introduction of 
alterations into the seed complementary sites; n=4, *p< 0.05. (G, H) Phase images (G) and 
quantification (H) of the colony size of the control and miR-29b-expressing T4-2 cells in 3D 
culture. (I, J) Phase images (I) and quantification (J) of the invasive branch structures in 
control and miR-29b-expressing MDA-MB 231 cells. (K, L) Spearman correlation analysis 
showed the negatively correlated expression of Hsp47 and miR-29b, 29c in human breast 
cancer tissues, n=97.
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Figure 5. MiR-29b/Hsp47 axis is regulated by the TGF-β pathway during breast cancer 
progression
(A) Spearman correlation analysis showed the correlated expression of Hsp47 and TGFB3 
in human breast cancer tissues, n=97. (B) Hsp47 expression was measured by quantitative 
RT-PCR in control and TGF-β treated S1 and MCF10A cells. The cells were treated with 
TGF-β (5ng/ml) for 48 hours, n=4, *, p<0.05. (C) Hsp47 expression was assessed by 
Western blot in control and SB431542treated MDA-MB 231 cells. Cells were treated with 
SB431542, a TGFBR inhibitor, for 48 hours. (D) MiR-29b expression in control and TGF-β 
treated MCF10A cells was analyzed by quantitative PCR analysis, n=4, ** p<0.01. (E) 
Quantitative PCR analysis of miR-29b expression in the control and SB431542 treated 
MDA-MB 231 cells, n=4, * p<0.1. (G) MDA-MB 231 cells were treated with SB431452 for 
12 hours, and then transfected with miR-29b or 29c inhibitors. Hsp47 expression was 
assessed by Western blot. (H) Spearman correlation analysis showed a negative correlation 
between miR-29b and TGFB3 levels in human breast cancer tissues, n=97.
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Figure 6. Silencing Hsp47 inhibits tumor growth in vivo
(A) Control or Hsp47-silenced T4-2/Luciferase cells were subcutaneously injected into 
SCID mice. IVIS images showed the tumor size in each group after 6 weeks. (B) The curves 
illustrated tumor growth of control and Hsp47-silenced T4-2 cells in SCID mice over time; 
n=6, * p<0.05. (C) Quantification of Ki67 staining, indicative of cell proliferation, in control 
and ShHsp47-expressing tumors; ** p<0.01. (D) Masson's trichrome staining of tumor 
sections (blue, collagen; black, nuclei; red, cytoplasm); scale bar, 200μm. The bar graph 
illustrated the collagen staining- area in tumors formed by control and Hsp47-silenced T4-2 
cells. (E) Control or Hsp47-silenced MDA-MB 231/Luciferase cells were injected into the 
fat pads of SCID mice. IVIS images showed tumors in representative mice from each group. 
The bar graph showed that tumor volume formed by Hsp47-silenced cells was significantly 
reduced compared with control cells; n=6, ** p<0.01.
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Figure 7. Increased Hsp47 expression is associated with poor prognosis
(A, B) Kaplan-Meier survival analysis showed the association of Hsp47 expression with the 
overall survival (A) and the recurrent-free survival in human breast cancer patients (B). The 
tumor samples were classified as low (n=137), high (n=138), and moderate (n=138) based 
on the mRNA levels of Hsp47 in the published microarray datasets. Significant differences 
in survival time were calculated using the Cox proportional hazard (log-rank) test. (C) Bar 
graph showing the mRNA levels of Hsp47 in different stages of breast cancer. Data were 
from Dr. Chin's microarray dataset. (D, E) Kaplan-Meier survival analysis showed the 
association of miR-29b (D) and 29c (E) expression with the overall survival in human breast 
cancer patients. The tumor samples were classified as low (n=33) and high (n=66) based on 
the mRNA levels of miR-29b and 29c in the published microarray datasets. Significant 
differences in survival time were calculated using the Cox proportional hazard (log-rank) 
test.
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